![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:8057X Cambridge Antibody Tech Group PLC 25 January 2001 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 David Chiswell, CEO John Aston, Finance Director Rowena Gardner, Head of Corporate Communications HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Adam Michael David Speechley ELAN Corporation Tel: 001 212 407 5740 Max Gershenoff BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext 17 (media) Brandon Lewis, ext.15 (investors) CAMBRIDGE ANTIBODY TECHNOLOGY AND ELAN CORPORATION, PLC CREATE MAJOR ALLIANCE FOR HUMAN MONOCLONAL ANTIBODIES IN NEUROLOGICAL DISEASE Melbourn, UK and Dublin, Ireland Cambridge Antibody Technology (LSE: CAT) and Elan Corporation, plc (NYSE: ELN) today announced a strategic partnership committed to the development of novel therapeutics for the treatment of human neurological disorders. The companies will jointly discover and develop antibody-based therapeutics targeted at a variety of neurological diseases and disorders. CAT will contribute its proprietary antibody phage display technology and high throughput screening capabilities to the alliance, which will capitalise on Elan's proven track record in drug discovery and development of treatments for neurological disorders. Under the terms of the four year agreement, the two companies will fund all research and development jointly and share commercialisation profits equally. CAT will have primary responsibility for the discovery and optimisation of human antibodies against multiple targets identified by Elan. Elan will evaluate clinical antibody candidates in pre-clinical models, manage clinical and regulatory development and will be responsible for global commercialisation. Elan and CAT together have already identified over 40 targets in the field that will immediately become the focus of this alliance. Commenting on the alliance, Dr. David Chiswell, CEO of CAT said "This is a unique opportunity to combine CAT's powerful human antibody technology with the expertise of Elan to take cutting edge therapeutic products for neurological disease all the way to the market. This exciting new alliance represents the commitment of yet another world leading company to CAT's approach of integrated, customised antibody drug development. This reflects CAT's objective, stated last year, to invest in building our drug pipeline. Elan and CAT share the view that the significant unmet medical need in a wide range of neurological diseases may be met by a portfolio of human antibody-based drugs". Commenting further, Donal J. Geaney, Chairman and CEO of Elan, said "This alliance with CAT, a leading company in antibody technology, strengthens Elan's commitment to basic research in the area of neurological disorders. We are truly excited by the potential for novel therapeutics to emerge from the synergistic combination of our experienced neurological research group with the accomplished scientists at CAT". Notes to Editors: Cambridge Antibody Technology (LSE: CAT) CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 200 people. CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. A secondary offering in March 2000 raised #93m. CAT has a world-leading platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT works in partnership with other companies at all stages of the drug discovery and development process. CAT's collaborations, past and present, include: AstraZeneca, BASF Pharma, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst and Zyomyx. Elan Corporation Elan Corporation, plc is a leading worldwide fully integrated pharmaceutical and drug delivery company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan is focused on the discovery, development and marketing of therapeutic products and services in neurology, pain management, oncology, infectious disease, dermatology and on the development and commercialisation of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions